Corporate Leadership Challenges - Compassionate Use & Expanded Access




Download Your Copy

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.

“If you only have a limited number of doses of an experimental medicine, what do you do with that?  Do you make it available for expanded access or do you gain more data for your ultimate drug approval?”– Kenneth Moch.


Kenneth I. Moch is the former President & CEO of Chimerix, Inc., an antiviral therapeutics company. In March/ April 2014, Ken guided Chimerix through a media firestorm around compassionate use of an early-stage developmental drug. Andrea Charles, Editor for Pharma IQ, speaks to Ken one year on about the leadership challenges and ethical dilemmas surrounding compassionate use and expanded access programs in drug development, lessons learnt and opportunities for the future.

Have Your Say
Rate this feature and give us your feedback in the comments section below
To continue reading this story

Learn More   Existing Users